| Patents for A61P 39 - General protective or antinoxious agents (19,019) |
|---|
| 01/23/2003 | WO2003006073A1 A composition and uses therefor for combating hangover |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002047456A3 Urotensin-ii receptor antagonists |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | CA2453159A1 A composition and uses therefor for combating hangover |
| 01/23/2003 | CA2452476A1 Mediating the effects of alcohol consumption by orally administering active dry yeast |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1165537B1 Hydroxymatairesinol in cancer prevention |
| 01/22/2003 | EP0937085B1 Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
| 01/22/2003 | CN1391934A Chinese medicine prepn for expelling toxin and resisting cancer and its preparing method and use |
| 01/22/2003 | CN1099413C Certain fused N-pyrrolylaniline: new class of GABA brain receptor ligand |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/17/2003 | WO2002006214A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/17/2003 | CA2415954A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/16/2003 | WO2003003995A1 Composition for oral hygiene comprising a fluoride ion vector and an antioxidant |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | US20030013771 Concurrent administering with drug; side effect reduction; central nervous system disorders |
| 01/16/2003 | US20030013748 Anticancer agents |
| 01/16/2003 | US20030012831 Liquid-liquid extraction being carried out in the first stage at a pH-value of about 4; treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence. |
| 01/16/2003 | US20030012774 Mixture of gamma-cyclodextrin and coenzyme Q1O is treated by homogenisation and inputting energy. |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274418A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage |
| 01/15/2003 | EP1274417A2 Treatment of movement disorders with metabotropic glutamate receptor antagonists |
| 01/15/2003 | EP1274413A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274319A2 Compositions and methods for improving vascular health |
| 01/15/2003 | EP0925287B1 Heterocyclic metalloprotease inhibitors |
| 01/15/2003 | EP0722442B1 Polyazacycloalkanes as dichelants |
| 01/15/2003 | EP0584347B1 Enantiomeric hydroxylated xanthine compounds |
| 01/15/2003 | CN1391571A Heterocyclic compounds and their use as medicines |
| 01/15/2003 | CN1391556A IL-8 receptor antagonists |
| 01/15/2003 | CN1391474A 5-membered heterocycle derivatives, production thereof and use as medicaments |
| 01/15/2003 | CN1391468A Pharmaceutical compositions comprising adenosine receptor agonist or antagonist |
| 01/14/2003 | US6506928 Derivative in which fullerene is linked to at least one dendron having at least one protic group which imparts water solubility |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002113A1 Vitamin c compositions |
| 01/09/2003 | WO2002064110A3 Carotenoid-loaded liposomes |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2001097793A3 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008846 Use of dopamine receptor antagonists in palliative tumor therapy |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2420548A1 Composition comprising vitamin c and a pyrone or furanone compound |
| 01/08/2003 | EP1272505A1 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives |
| 01/08/2003 | EP1272504A1 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272201A2 Use of compatible solutes as substances having free radical scavenging properties |
| 01/08/2003 | EP1272172A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/08/2003 | EP0863878B1 Cyclic nitrones and pharmaceutical compositions containing them |
| 01/08/2003 | CN1390118A Dextrose and insulin fluid formulation for intravenous infusion |
| 01/07/2003 | US6503923 Haloalkoxy imidazonaphthyridines |
| 01/03/2003 | WO2003000633A2 A process for the isolation of a major harmful oxidant from cigarette smoke |
| 01/03/2003 | WO2003000073A1 Method for processing ginseng and processed ginseng obtained by the same |
| 01/03/2003 | WO2001089502A3 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004131 Oenothein medicaments |
| 01/02/2003 | US20030003120 A phenolic fraction of fruit obtained from the Rosaceae family, including at least 10% by weight of the sum of phloridzin, chlorogenic acid, epicatechin, quercitrin, procyanidin B2, p-coumaric acid and caffeic acid |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | EP1268759A2 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 01/02/2003 | EP1268305A1 Infusion packet with useful and decorative elements, support member, delivery system and method |
| 01/02/2003 | EP1267901A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 01/02/2003 | EP1267891A2 Antiadhesive carbohydrates |
| 01/02/2003 | EP1267881A2 Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies |
| 01/02/2003 | EP1267863A2 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents |
| 01/02/2003 | EP1267857A1 Method of inhibiting the expression of inflammatory cytokines and chemokines |
| 01/02/2003 | EP1267822A2 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light |
| 01/02/2003 | EP1267616A1 Methods of modulating hair growth |
| 01/02/2003 | EP0806960B1 Extracts of shark cartilage, process of production and uses thereof |
| 01/01/2003 | CN1387858A Prepn of high-selectivity heavy metal lead repellent |
| 12/31/2002 | US6500868 Method for preventing and treating peripheral neuropathy by administering selegiline |
| 12/31/2002 | US6500458 Condensate of SAR abolisher, producing method thereof, and SAR abolisher powder |
| 12/31/2002 | CA2097732C Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus |
| 12/30/2002 | WO2002002582A1 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same |
| 12/30/2002 | CA2414605A1 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same |
| 12/27/2002 | WO2002056907A3 Molecular antigen array presenting amyloid beta |
| 12/26/2002 | US20020198248 Therapeutic methods and compositions involving isoflavones |
| 12/26/2002 | US20020198219 2-pyridinamine compositions and related methods |
| 12/26/2002 | US20020198208 Medicinal preparation and process for manufacturing thereof |
| 12/25/2002 | CN1387526A Cyclopropanes as CGRP antagonists, medicaments contg. said compounds and method for production thereof |
| 12/25/2002 | CN1387512A Positive modulators for nicotinic receptor agonists |
| 12/25/2002 | CN1386502A Application of niflumic acid in preventing and treating arrhythmia |
| 12/19/2002 | WO2002100392A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| 12/19/2002 | WO2002100347A2 Prodrugs of gaba analogs, compositions and uses thereof |
| 12/19/2002 | WO2002087604A3 Preparations containing a combination of vitamin e and afamin |
| 12/19/2002 | WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 12/19/2002 | WO2002058626A9 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 12/19/2002 | US20020193412 Compounds and compositions for treating tissue ischemia |
| 12/19/2002 | US20020192334 Method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby |
| 12/19/2002 | CA2449673A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| 12/18/2002 | EP1266660A1 Heme oxygenase-1 inducers or induction enhancers |
| 12/18/2002 | EP1265860A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |